2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hydrochloride, (S)- → Timolol

HRID 1826578ノート

反応式

HRID 1826578 の反応式
[CH3:1][C:2]([NH:5][CH2:6][C@H:7]([OH:21])[CH2:8][O:9][C:10]1[C:11]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)=[N:12][S:13][N:14]=1)([CH3:4])[CH3:3].Cl>C([O-])(=O)C>[CH3:4][C:2]([NH:5][CH2:6][C@H:7]([OH:21])[CH2:8][O:9][C:10]1[C:11]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)=[N:12][S:13][N:14]=1)([CH3:1])[CH3:3]

参加物

3

反応物 1

HCID 1552082-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hydrochloride, (S)-

生成物 1

HCID 33624Timolol

試薬・触媒・溶媒 1

HCID 175Acetate溶媒

実験手順

Timolol HCl (3-tert-butylamino-1-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol) is a beta-blocker for treatment of glaucoma. The drug is dissolved in a final concentration of 0.5% (m/v) in 20 mM acetate buffer pH 5.2. After the addition of chitosan-4-thio-butyl-amidine conjugate in a final concentration of 0.1% (m/v) and a preservative in a final concentration of 0.03% (m/v), the pH-value is readjusted to pH 5.2. Remaining oxygen is removed by bubbling the solution with nitrogen. The resulting eye drops are filled up under inert conditions in multiple unit vessels of 10 ml. The vessels are than sealed with an aluminium-foil.

後処理

  1. customRemaining oxygen is removed
  2. customby bubbling the solution with nitrogen
  3. additionThe resulting eye drops are filled up under inert conditions in multiple unit vessels of 10 ml
  4. customthan sealed with an aluminium-foil

出典と根拠

ORDレコード
ord-ac5a061bae6440cf8c1547d75a44897e
出典データセット
uspto-grants-2006_05
特許番号
US07053068B2

反応ノート

読み込み中…